physicians

omicron

fracture toughness

neck dissection

sars-cov_88512

publication date

sars-cov_104446

fungal keratitis

sars-cov_137437

sars-cov_102729

vaccine_53291

renal_125924

sars-cov_55575

journal operational research

convalescent

price dynamics

hydrocolloid

mrna vaccines

Science

In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as correlates of protection. These immune markers were measured at the time of second vaccination and 4 weeks later, with values reported in standardized World Health Organization international units. All markers were inversely associated with COVID-19 risk and directly associated with vaccine efficacy. Vaccine recipients with postvaccination 50% neutralization titers 10, 100, and 1000 had estimated vaccine efficacies of 78% (95% confidence interval, 54 to 89%), 91% (87 to 94%), and 96% (94 to 98%), respectively. These results help define immune marker correlates of protection and may guide approval decisions for messenger RNA (mRNA) COVID-19 vaccines and other COVID-19 vaccines.

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial